Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells

Molecular Endocrinology

Volumn 15, Issue 8, 2001, Pages 1344-1359

  Oh, Annabell S ^a   Lorant, Lori A ^a   Holloway, Jamie N ^a   Miller, David L ^a,b   Kern, Francis G ^a,c   El Ashry, Dorraya ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; DNA METHYLATION; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RIBONUCLEASES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034899503     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.15.8.1344     Document Type: Article

References (86)

1. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer
2. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer
3. Steroid receptors and other prognostic factors in primary breast cancer
4. How to use prognostic factors in axillary node-negative breast cancer patients
5. Signalling by receptor tyrosine kinases
6. Acquired tamoxifen resistance in human breast cancer - Potential mechanisms and clinical implications
7. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
8. Expression of epidermal growth factor receptor and c-erB2 during the development of tamoxifen resistance in human breast cancer
9. Tamoxifen for early breast cancer: An overview of the randomized trials
10. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
11. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer
12. Epidermal growth factor receptor (EGFR) status associated with failure of primary endocrine therapy in elderly post-menopausal patients with breast cancer
13. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer
14. Epidermal growth factor receptor (EGFR); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
15. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer
16. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer
17. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression
18. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
19. cv-erbB-2 oncogene as a prognostic marker in breast cancer
20. Expression of the 21,000 molecular weight Ras protein in a spectrum of benign and malignant human mammary tissues
21. Ras gene alterations and enhanced levels of Ras p21 expression in a spectrum of benign and malignant human mammary tissues
22. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer
23. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry
24. A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines
25. Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor
26. Role of epidermal growth factor receptor expression in primary breast cancer: Results of a biochemical study and an immunocytochemical study
27. Transfection of v-RasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity
28. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice
29. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
30. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
31. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
32. Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells
33. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture
34. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens
35. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo
36. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone- independent tumor growth in vivo
37. The role of estrogen in the regulation of EGFR expression
38. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis
39. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique
40. Expression of estrogen receptor and its messenger ribonucleic acid in the MCF-7 cell line: Multiparametric analysis of its processing and regulation by estrogen
41. Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: An inverse correlation to progesterone receptor levels
42. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors
43. Regulation of the estrogen receptor in MCF-7 cells by estradiol
44. Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF-7 breast cancer cells
45. Protein synthesis is not implicated in the ligand-dependent activation of the estrogen receptor in MCF-7 cells
46. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
47. Transformation of mammalian cells by constitutively active MAP kinase
48. Human transforming growth factor-α contains an estrogen responsive element comprised of two imperfect palindromes
49. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors
50. Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2
51. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
52. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
53. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
54. Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth
55. Dopaminergic and ligand-independent activation of steroid hormone receptors
56. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone
57. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor
58. ICI 164,184, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness
59. Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen- like response to epidermal growth factor
60. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element
61. Progesterone receptor regulation in uterine cells: Stimulation by estrogen, cyclic adenosine 3′,5′-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors
62. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen
63. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I
64. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators
65. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells
66. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
67. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol
68. Recombinant insulin-like growth factor binding protein-1 inhibits IGF- I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells
69. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I
70. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines
71. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells
72. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth
73. Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family
74. Methylation of estrogen and progesterone receptor genes 5′ CpG islands correlates with ER and PR gene expression in breast tumors
75. Mapping of ER gene CpG island methylation-specific polymerase chain reaction
76. Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells
77. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes
78. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK
79. Inhibition of PDGF and EGF-mediated mitogenesis and signaling in 3T3 cells expressing δ Raf-1:ER, an estradiol-regulated form of Raf-1
80. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase
81. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies
82. Immunologic analysis of human breast cancer progesterone receptors. 1. Immunoaffinity purification of transformed receptors and production of monoclonal antibodies
83. 17α-estradiol is a biologically active estrogen in human breast cancer cells in tissue culture
84. Single step method of RNA isolation by acid guanidinium thiocyanate phenolchloroform extraction
85. Effects of 12-O-tetradecanoylphorbol-13-acetate on estrogen receptor activity in MCF-7 cells
86. High-efficiency transformation of mammalian cells by plasmid DNA